{"prompt": "['Novartis', 'Confidential', 'Page 41', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '5.6.3 Withdrawal of informed consent', 'Patients may voluntarily withdraw consent to participate in the study for any reason at any', 'time.', 'Withdrawal of consent (WoC) occurs only when a patient does not want to participate in the', 'study anymore and does not want any further visits or assessments and does not want any', 'further study related contacts and does not allow analysis of already obtained biologic', 'material. A patient is NOT considered to have withdrawn consent if they agree to follow-up', 'visits.', 'If a patient withdraws consent, the investigator must make every effort (e.g. telephone, e-mail,', 'letter) to determine the primary reason for this decision and record this information. Study', 'treatment must be discontinued and no further assessments conducted. All biological material', 'that has not been analyzed at the time of withdrawal must not be used. Further attempts to', 'contact the patient are not allowed unless safety findings require communicating or follow-up.', '5.6.4 Lost to follow-up', 'For randomized patients who are lost to follow-up (i.e. those patients whose status is unclear', 'because he/she fails to appear for study visits without stating an intention to withdraw), the', 'investigator should show \"due diligence\" by making appropriate efforts to re-establish contact', 'with patient and attempts to contact the patient should be documented in the source', 'documents, e.g. dates of telephone calls/emails, registered letters, etc. If contact has not been', 're-established, all efforts should still be made to locate the patient and obtain information at', 'the end of the 24 weeks intended treatment and at the safety follow-up visit (Visit 301). A', 'patient cannot be considered as lost to follow-up until the time point of his/her scheduled end', 'of study visit has passed.', '5.6.5 Early study termination by the sponsor', 'The study can be terminated at any time for any reason by Novartis. Should this be necessary,', 'the patient should be seen as soon as possible and treated for a prematurely withdrawn patient.', 'The investigator may be informed of additional procedures to be followed in order to ensure', \"that adequate consideration is given to the protection of the patient's interests. The\", 'investigator will be responsible for informing the Institutional Review Board/Independent', 'Ethics Committee (IRBs/IECs) of the early termination of the trial.', '6 Visit schedule and assessments', 'Table 6-1 lists all the assessments to be performed for the study and indicates with an \"X\" the', 'visits at which they will be performed. Patients should be seen for all visits on the designated', 'day or as close as possible to that date. Visits during the treatment period should be performed', 'within +/- 7 days of the designated day or as close as possible. All data obtained for these', \"assessments must be supported in the patients' source documentation.\", 'The following assessments are scheduled to be performed in order as follows: Patient reported', 'outcome (PRO) questionnaires (i.e. AQLQ, ACQ,', '), ECG, Vital signs (pulse rate', 'and blood pressure), blood sample/urine samples, followed by spirometry in a manner that the']['Novartis', 'Confidential', 'Page 42', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'spirometry measurements occur at the scheduled time point (See Table 6-2 for Timed', 'Assessments).', 'Whenever other assessments are scheduled at the same time-point, spirometry must take', 'precedence such that it occurs at the scheduled time point or as near as possible. As required,', 'other assessments can be done after spirometry.', 'Table 6-1 Assessment schedule', 'Period', 'Screening', 'Run-in', 'Treatment', 'Follow-up', 'Study', 'Completion', 'Visit number', '1', '101', '201', '202', '203', '204', 'TD', '3014', 'Day', '-21 to -14', '-14', '1', '57', '113', '169', '176', 'Week', '-3 to -2*', '-2', '0', '8', '16', '24', '25', 'Obtain Informed consent', 'X', 'Contact IRT (IVRS/IWRS)', 'S', 'S', 'S', 'S', 'S', 'S', 'S', 'S', 'Prior and Current medication', 'X', 'review/adjustment', 'Review Concomitant medication', 'X', 'X', 'Review Surgery and Procedures', 'X', 'X', 'Inclusion/Exclusion criteria review', 'X', 'X', 'Relevant', 'Medical', 'History,', 'Demography', 'History of Asthma Exacerbation', 'Physical examination', 'S', 'S', 'S', 'Smoking history and status', 'X', 'Issue/collect rescue medication as', 'S', 'S', 'S', 'S', 'S', 'S', 'required and review use', 'Pregnancy test (serum)', 'X', 'Pregnancy test (urine)\u00b9', 'X', 'Antigen-Specific IgE (Immunocap)', 'X', 'Serum Total IgE', 'X', 'Vital signs', 'X', 'X', 'ECG', 'X', 'X', 'Height', 'X', 'Weight', 'X', 'X']\n\n###\n\n", "completion": "END"}